A Phase 2 Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine (Fluad), Formulation 2012/2013, When Administered to Elderly Subjects

Trial Profile

A Phase 2 Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine (Fluad), Formulation 2012/2013, When Administered to Elderly Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 28 Jan 2014 According to European Clinical Trials Database record the trial is discontinued in Italy; ongoing in Belgium.
    • 24 Jan 2014 As per ClinicalTrials.gov record primary endpoints were modified: hemagglutination inhibition (HI) endpoint deleted; local and systemic reactions endpoint changed to secondary, time frame of primary endpoints changed from day 21 to day 22.
    • 29 Sep 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2012-000085-38).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top